LOGIN  |  REGISTER
Terns Pharmaceuticals
Terns Pharmaceuticals

Spok to Present and Host 1x1 Investor Meetings at the 35th Annual Piper Sandler & Co. Healthcare Conference

November 16, 2023 | Last Trade: US$16.13 0.43 -2.60

ALEXANDRIA, Va. / Nov 16, 2023 / Business Wire / Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced that Vincent D. Kelly, chief executive officer, will participate in the 35th annual Piper Sandler & Co. healthcare conference on November 29, 2023 in New York. The Company’s presentation is scheduled for 12:30 pm ET. Spok will also host a series of 1X1 meetings with investors on November 29, 2023.

The presentation will also be webcast and can be accessed via the conference presentation link, and in the investor relations section of the Company's website: http://www.spok.com.

About Spok

Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Alexandria, Virginia, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Care Connect® platform to enhance workflows for clinicians and support administrative compliance. Our customers send over 70 million messages each month through their Spok® solutions. Spok enables smarter, faster clinical communication. For more information, visit spok.com.

Spok is a trademark of Spok Holdings, Inc. Spok Care Connect and Spok Mobile are trademarks of Spok, Inc.

Recursion

Stock Quote

Last Trade: US$16.13
Daily Change: -0.43 -2.60
Daily Volume: 200,702
Market Cap: US$332.120M

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page